Ashvattha Therapeutics, Clearside Biomedical, ZEISS preview EURETINA presentations

Clearside Biomedical, ZEISS and Ashvattha Therapeutics are amongst the companies presenting and showcasing highlights during the 2025 European Society of Retina Specialists (EURETINA) from September 4-7 in Paris, France. Here, a preview of what to expect from the companies.

Companies are listed in alphabetical order.

Ashvattha Therapeutics to present late-breaking phase 2 data at EURETINA 2025

Ashvattha Therapeutics will present topline 40-week phase 2 study findings on migaldendranib (MGB) for the treatment of diabetic macular oedema (DMO) and neovascular age-related macular degeneration (nAMD) at the 2025 EURETINA Congress.¹

The company is focused on developing a nanomedicine therapeutic that traverses the blood-retinal barrier in regions of inflammation, selectively targeting and reprogramming activated cells in the retina. MGB, Ashvattha’s investigational subcutaneous nanomedicine in development for the treatment of DME and nAMD, is designed to cross the blood-retinal barrier in regions of inflammation and selectively normalise VEGF expression in activated retinal cells.¹

Ashvattha forums at EURETINA 2025

The Future of Tyrosine Kinase Inhibitors & Other Adjunctive Agents for AMD: Exists or Busts?

• Panelist: Susan Schneider, MD, Acting Chief Medical Officer of Ashvattha Therapeutics
• Date: Wednesday, September 3
• Time: 11:50 – 12:20 CEST

Company Presentations 1

• Presenter: Susan Schneider, MD, Acting Chief Medical Officer of Ashvattha Therapeutics
• Date: Wednesday, September 3
• Time: 13:50 – 15:20 CEST

Subcutaneous Migaldendranib for the Treatment of Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration: First Time 40-week Results from Phase 2 Trial

• Presenter: Arshad M. Khanani, MD, MA, FASRS, Director of Clinical Research at Sierra Eye Associates
• Session: EURETINA Session 7 – First Time Clinical Trials & Late Breaking Session
• Date: Friday, September 5
• Time: 15:27 – 15:33 CEST

Clearside Biomedical to present on suprachoroidal delivery

Clearside, focused on the suprachoroidal space (SCS) and the delivery of therapies to the back of the eye, said the company will be highlighting its SCS delivery platform and CLS-AX programme.² The delivery platform is designed to enable targeted treatment for multiple retinal diseases, including wet AMD, diabetic retinopathy, DMO, geographic atrophy and ocular cancer.

CLS-AX (axitinib injectable suspension) is described as “a proprietary suspension of axitinib," which is a tyrosine kinase inhibitor (TKI), for suprachoroidal injection.²

“We are excited to showcase our SCS Microinjector platform and advancements with our CLS-AX program at these prominent medical meetings in Europe,” Victor Chong, MD, MBA, chief medical officer and EVP, head of research and development, said in a press release.²

“For CLS-AX, we have designed a phase 3 trial in wet AMD in alignment with the US FDA and a new, streamlined phase 2 trial design in non-proliferative diabetic retinopathy. In addition, we believe suprachoroidal delivery has the potential to provide a targeted approach for the treatment of geographic atrophy, enabling drug dispersion directly to the choroid and retina while potentially minimising systemic and anterior segment side effects. This method may offer improved efficacy for small molecules and complement inhibition in both the retinal pigment epithelium and choroid,” Chong said in the release.

Presentations from Clearside Biomedical

25^th EURETINA Congress presentations

Suprachoroidally Administered CLS-AX in Participants with Neovascular Age-Related Macular Degeneration: Phase 2b Results from ODYSSEY and Phase 3 Program Update

• Presenter: Sobha Sivaprasad, MD, Professor of Retinal Clinical Research, Consultant Ophthalmologist, Moorfields Eye Hospital, London, UK
• Date: Saturday, September 6
• Time: 16:06 – 16:12 CEST

A Decade-Long Review of the Evolution of Suprachoroidal Drug Delivery with a Focus on Axitinib Injectable Suspension for Neovascular Age-Related Macular Degeneration

• Presenter: Victor Chong, MD, MBA, Chief Medical Officer and EVP, Head of Research and Development
• Date: Saturday, September 6
• Time: 14:27 – 14:33 CEST

Suprachoroidal gene therapy for diabetic retinopathy (ALTITUDE study)

• Presenter: Lejla Vajzovic, MD, Associate Professor of Ophthalmology at Duke University School of Medicine
• Date: Thursday, September 4
• Time: 11:13 – 11:20 CEST

Ophthalmology Futures Retina Forum presentations

Geographic Atrophy & Intermediate AMD: Lessons Learned from Glaucoma & Other Chronic Disease

• Panelist: Victor Chong, MD, MBA, Chief Medical Officer and EVP, Head of Research and Development
• Date: Wednesday, September 3
• Time: 18:40 – 19:10 CEST

ZEISS to showcase comprehensive workflow for retina care

ZEISS Medical Technology announced it will be showcasing its latest portfolio, which ranges from pathology detection and assessment to planning and treatment.³

“At ZEISS, we continue to enhance the ZEISS Retina Workflow with new capabilities to help empower clinicians who are redefining vitreoretinal surgery and advance retinal care,” Magnus Reibenspiess, head of strategic business unit (ophthalmology) at ZEISS, said in a press release.³

“We’re excited to continue leading in this area and meeting the evolving needs of surgeons from around the world with one of the few end-to-end retina ecosystems in the industry.”

The company is also introducing TDC VELOCE from Dutch Ophthalmic Research Center (DORC) during the conference.³ TDC VELOCE is a new high-speed cutter for the EVA NEXUS phacovitrectomy system that enables SMART IOP for posterior surgery to provide constant intraoperative stability. TDC VELOCE combines performance, control, stability and a new ergonomic design that offers improved aspirational flow for 25G/27G, a higher cut speed of up to 20k CPM.³

“By combining the strengths of ZEISS and DORC, we’re reducing complexity to help enable retina specialists around the world to diagnose earlier, treat with greater precision, and monitor more effectively—through an expanding connected workflow,” Pierre Billardon, Head of Business Sectors Surgery Posterior Segment at ZEISS and CEO of DORC International, said in a press release.3

ZEISS portfolio highlights at EURETINA 2025

CIRRUS Pathfinder: CIRRUS Pathfinder, which recently received a CE mark from the European Commission, is an artificial intelligence (AI) tool to assist in automatically identifying abnormal macular OCT B-scans. The latest CIRRUS software release features PathFinder, which uses proprietary deep learning algorithms to support OCT interpretation and improve OCTA image quality and multi-layer segmentation to support elevated diagnostic workflows and enhanced patient care.

CLARUS 700 with ICGA: The updated CLARUS software offers high-resolution early-phase to late-phase ultra-widefield imaging. The technology also features standalone ICG, simultaneous GA-ICG capture, and an added movie mode for all angiography modalities, such as standalone FA, standalone ICG, and simultaneous FA-ICG.

ZEISS Research Data Platform (RDP): ZEISS RDP is designed for multi-center research and real-world clinical evidence. This platform is could-based and AI-driven, which offers retina specialists the ability to take a clinical hypothesis and turn it into measurable outcomes.

Learn about the ZEISS Retina Workflow at EURETINA 2025

Attendees can visit the ZEISS booth, #2.B20 for the following:

Thursday, September 4 from 10:00 – 10:30 CEST

Experience how the ZEISS RDP enables retina specialists to train AI models, generate biomarkers, and scale collaborative research across institutions.

Thursday, September 4 from 2:30 – 3:00 CEST

Ricardo Leitão Guerra, MD, MSc, FICO, will be presenting, “ZEISS Retina Workflow in the Real World: OCTA, FA, ICGA in Clinical Application.”

Friday, Sept 5 from 2:30 – 3:00 CEST

Harvey Uy, MD, will be presenting, “Clinical Study Results: Comparison of image review parameters from two different optical coherence tomography analytical workflows.”

Reference:

1. Ashvattha Therapeutics. Ashvattha Therapeutics to Present Late-Breaking Phase 2 DME and nAMD Data at 25th EURETINA Congress. Yahoo Finance. Published August 26, 2025. Accessed August 27, 2025. https://finance.yahoo.com/news/ashvattha-therapeutics-present-breaking-phase-120000056.html

2. Clearside Biomedical. Published August 26, 2025. Accessed August 27, 2025. https://ir.clearsidebio.com/news-releases/news-release-details/clearside-biomedical-announces-multiple-presentations

3. Zeiss C. ZEISS showcases comprehensive workflow for full spectrum of retina care at EURETINA. Prnewswire.com. Published August 26, 2025. Accessed August 27, 2025. https://www.prnewswire.com/news-releases/zeiss-showcases-comprehensive-workflow-for-full-spectrum-of-retina-care-at-euretina-302538494.html